Key result
Advanced reperfusion therapies are utilized in only ~33% of high-risk pregnancy-associated PEs despite high mortality.
Why the study?
Data on managing acute PE during pregnancy are limited because pregnant women are systematically excluded from interventional trials, despite PE being the leading preventable cause of maternal death in high-income countries.
Advanced reperfusion therapies are used in approximately one-third of high-risk pregnancy-associated pulmonary embolism cases and carry substantial risks of in-hospital mortality and major bleeding.
Answers are grounded in this paper and cite their sources.
May warrant caution with advanced reperfusion in pregnancy-associated PE; leaves open optimal management pending dedicated trials.
Background Pulmonary embolism (PE) remains the leading preventable cause of maternal death in high-income countries. Data on the management of acute PE during pregnancy are limited because pregnant women are systematically excluded from interventional trials. We evaluated the use and outcomes of advanced reperfusion therapies in pregnancy-associated PE. Methods We performed a cross-sectional analysis of the US Nationwide Inpatient Sample from 2016 through 2020. Pregnancy- and puerperium-related hospitalizations were identified using ICD-10-CM codes. High-risk PE was defined by shock, mechanical ventilation, cardiac arrest, cardiopulmonary resuscitation, or vasopressor support. Advanced reperfusion therapies included systemic thrombolysis (ST), catheter-directed therapy (CDT), surgical embolectomy, and venoarterial extracorporeal membrane oxygenation (VA-ECMO). Results Among 19,741,880 pregnancy- or puerperium-related hospitalizations, 12,715 (0.06%) were complicated by PE, corresponding to 6.7 (95% CI, 6.6–6.8) hospitalizations per 10,000 live births. The overall in-hospital mortality rate was 0.86% (0.058 [95% CI, 0.048–0.070] deaths per 10,000 live births). Mortality was 0.2% among patients without hemodynamic instability and 29.1% among those with high-risk PE. Advanced reperfusion therapies were used in 3.4% of all pregnancy-associated PE cases and in 32.7% of high-risk cases. In-hospital mortality was 9.8% after ST, 10.7% after CDT, and 50% after VA-ECMO. Major bleeding occurred in 15.7%, 10.7%, and 50%, respectively. Conclusions Pregnancy-associated PE is rare but associated with high mortality in high-risk presentations. Advanced reperfusion therapies are used infrequently, reflecting the limited evidence, highlighting the need for multidisciplinary managements, and further research and guidance.
No takes yet. Share an insight, caveat, or question.
Farmakis et al. (2026) studied this question. Advanced reperfusion therapies are utilized in only 32.7% of high-risk pregnancy-associated pulmonary embolisms, despite a 29.1% mortality rate in these hemodynamically unstable patients.
Synapse has enriched 10 related papers. Consider them for comparative context: